Lycopene and prostate cancer: a modest signal in prospective studies
A large review separates dietary lycopene, circulating lycopene and tomato intake rather than treating them as interchangeable.

Illustrative food image, not a photograph of the study intervention.
Three exposures, not one tomato claim
This 2025 review examined dietary tomato intake, dietary lycopene intake and blood lycopene levels in prospective studies. Those are three distinct exposures, and its reported results should remain attached to the exposure actually analyzed. The systematic review included 121 studies, with 119 entering the meta-analysis. Across follow-up periods ranging from two to 32 years, there were 108,574 cancer cases and 10,375 deaths. These totals describe the broad review rather than a prostate-only sample. The study is useful for examining associations over time, but prospective observation is not random assignment to a tomato-rich diet.
Balali A, Fathzadeh K, Askari G, Sadeghi O et al.. Frontiers in nutrition, 2025. PMID 40013157 · DOI
What the prostate result says
For prostate cancer, the abstract reports a linear inverse association with dietary lycopene intake: a pooled relative risk of 0.99, a 95% confidence interval of 0.97–1.00 and a P value of 0.045. Reported heterogeneity for that analysis was zero. The estimate is close to the null value of one, and the rounded confidence interval reaches one. Crucially, the abstract does not identify the intake increment attached to this prostate-specific estimate. It would therefore be inappropriate to translate it into a promised benefit per tomato, per serving of sauce or per milligram of a supplement.
Balali A, Fathzadeh K, Askari G, Sadeghi O et al.. Frontiers in nutrition, 2025. PMID 40013157 · DOI
Do not borrow a larger number from another endpoint
Some numbers in the review are larger than the prostate-specific association, but they answer different questions. High versus low dietary lycopene intake was associated with overall cancer risk at a relative risk of 0.95, while the corresponding comparison for blood lycopene was 0.89. Cancer mortality also had separate estimates: 0.89 for tomato intake and 0.84 for lycopene intake. Those are not prostate-incidence estimates and should not be presented as such. The review reported substantial heterogeneity for these mortality associations, including I-squared values of 65.7% for tomato intake and 86.5% for lycopene intake.
Balali A, Fathzadeh K, Askari G, Sadeghi O et al.. Frontiers in nutrition, 2025. PMID 40013157 · DOI
An association, not a tomato treatment trial
The review searched the literature through July 2023 and summarized prospective cohort findings, despite appearing in 2025. Its strongest practical lesson for interpreting a prostate headline is to keep the food, exposure and outcome labels intact. Dietary lycopene was associated with prostate-cancer risk; that does not establish a causal effect from prescribing tomatoes. Blood lycopene findings are a separate category, and overall cancer mortality is a separate endpoint. Nothing in the abstract supplies evidence that a particular tomato recipe treats established prostate cancer or identifies a supplement dose that reproduces the cohort associations reported here.
Balali A, Fathzadeh K, Askari G, Sadeghi O et al.. Frontiers in nutrition, 2025. PMID 40013157 · DOI